Welcome to our dedicated page for Merck & Co SEC filings (Ticker: MRK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Merck & Co., Inc. (NYSE: MRK) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, along with AI-powered summaries to help interpret complex documents. Merck is a New Jersey–incorporated biopharmaceutical preparation manufacturer whose common stock and multiple series of notes are registered on the New York Stock Exchange, as reflected in its Form 8-K filings.
Through this page, readers can review Merck’s current and historical filings, including Form 8-K reports on material events such as public offerings of long-dated notes under its automatic shelf registration statement on Form S-3ASR and announcements of restructuring programs. Filings related to quarterly and annual results, such as earnings releases furnished on Form 8-K, give additional context on the company’s financial condition and performance.
For a research-intensive company like Merck, core SEC filings such as annual reports on Form 10-K and quarterly reports on Form 10-Q (when available) are key sources for information on its human health and animal health businesses, major products like KEYTRUDA and GARDASIL, pipeline programs including WINREVAIR and Alzheimer’s disease candidates, risk factors and capital structure. Forms 3, 4 and 5, when filed, provide details on insider transactions by directors and officers.
Stock Titan enhances these filings with AI-generated explanations that highlight important sections, clarify technical language and point out items that may interest investors, such as new debt issuances, restructuring charges or significant acquisitions. Real-time updates from EDGAR help ensure that newly filed Merck documents, including 10-Ks, 10-Qs and Form 4 insider reports, appear promptly, allowing users to track regulatory disclosures related to MRK in a single, organized feed.
Merck & Co. (MRK) Form 4 – 5 Aug 2025: EVP & Chief Information & Digital Officer David M. Williams reported the vesting of 17,119 restricted stock units (RSUs) on 4 Aug 2025 (code M). The shares were issued at the market price of $79.29 and immediately reduced by 8,432 shares (code F) that the issuer withheld to cover tax obligations. Net increase to Williams’s direct ownership is +8,687 shares, bringing his total direct holding to 33,013.467 shares. The related RSU grant is now fully settled; no derivative securities remain.
The footnote clarifies a prior filing error: the RSUs were previously disclosed as vesting in three annual tranches, but actually vested in one installment on 4 Aug 2025. No other transactions, sales to the open market, or new option grants were disclosed.
Merck & Co., Inc. (NYSE: MRK) filed an 8-K disclosing two key items. Item 2.02 furnishes, but does not file, the company’s Q2-25 earnings press release (Ex. 99.1) and related supplemental information (Ex. 99.2); specific financial figures are not included in this filing.
Item 2.05 launches a new “2025 Restructuring Program.” Approved 25 Jul 2025, the plan targets sales, administrative and R&D head-count reductions, a smaller real-estate footprint and continued manufacturing network optimization. Merck expects:
- Total pretax charges: ≈ $3.0 billion; ~60 % cash (severance & contract terminations) and the balance non-cash (accelerated depreciation).
- Major actions largely finished by end-2027; manufacturing actions substantially done by end-2029.
- Annual cost savings: ≈ $1.7 billion realized by end-2027.
Merck & Co., Inc. (MRK) – Form 4 insider transaction filing
Director Christine E. Seidman reported two minor changes to her beneficial ownership as of 30 June 2025:
- Non-derivative securities: a disposition of 100 shares of Merck common stock (transaction code and price not disclosed). Her post-transaction direct holding is shown as 100 shares.
- Derivative securities: acquisition of 102.6402 phantom stock units at a reference price of $79.16. Phantom stock is settled 1-for-1 in cash after the director leaves the board under Merck’s Deferred Payment of Directors’ Compensation Plan. Total phantom units after the transaction stand at 18,495.8789.
No other equity awards, options, or material transactions were reported. Given Merck’s multibillion-dollar market capitalization, the size of these trades is immaterial and should not affect the company’s valuation or governance structure.